文献速递艾滋病与性传播感染

HIV相关中枢神经系统损害患者脑脊液对BIC/FTC/TAF的暴露

Cerebrospinal fluid exposure to bictegravir/emtricitabine/tenofovir in HIV-1-infected patients with CNS impairment.
PubMed 文献 · J Antimicrob Chemother · 2021-01-01

结果显示脑脊液中三种药物暴露均偏低,仅3例三药抑制商均大于1,年龄和血浆总浓度与脑脊液浓度正相关,作者提示51岁以下患者以该方案作一线治疗需谨慎。

要点

  • 脑脊液中游离比克替拉韦及恩曲他滨、替诺福韦总浓度均偏低,仅3例三药抑制商均大于1。
  • 年龄和血浆总浓度与三药脑脊液浓度正相关,51岁以上者脑脊液浓度更高。
  • 51岁以下HIV相关中枢神经系统损害患者以BIC/FTC/TAF作一线治疗需谨慎。

核心结论

  • HIV相关中枢神经系统损害患者脑脊液对比克替拉韦、恩曲他滨和替诺福韦暴露偏低。
  • 结果提示51岁以下HIV相关中枢神经系统损害患者以BIC/FTC/TAF作一线治疗应谨慎。

研究设计与样本

  • 患者接受含BIC/FTC/TAF的优化抗逆转录病毒治疗至少1个月,用LC-MS/MS测定血浆和脑脊液浓度。
  • 计算抑制商为游离(比克替拉韦)或总(恩曲他滨、替诺福韦)浓度与半数(或90%)最大抑制浓度之比,数值以中位数(范围)表示。

主要发现

  • 患者年龄45(26-68)岁。
  • 脑脊液游离比克替拉韦浓度为4.4(1.6-9.6)ng/mL,恩曲他滨总浓度为84.4(28.6-337.4)ng/mL,替诺福韦总浓度为1.6(0.7-4.3)ng/mL。
  • 脑脊液游离比克替拉韦比例为34%(15%-82%),血浆为0.33%(0.11%-0.92%)。
  • 3例患者三种抗逆转录病毒药物的抑制商均大于1。
  • 与脑脊液浓度(比克替拉韦为游离浓度)正相关的因素为年龄及三药的血浆总浓度;51岁以上患者脑脊液浓度更高。

临床怎么用

  • 对51岁以下HIV相关中枢神经系统损害患者,以BIC/FTC/TAF作一线治疗需谨慎并关注脑脊液药物暴露。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: The penetration of antiretroviral drugs into deep compartments, such as the CNS, is a crucial component of strategies towards an HIV cure. This study aimed to determine CSF concentrations of bictegravir, emtricitabine and tenofovir in patients with HIV-related CNS impairment (HCI) enrolled in a real-life observational study. METHODS: Patients with HCI treated by optimized ART, including bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) for at least 1 month were enrolled. Plasma and CSF concentrations were measured by quality control-validated assays (LC-MS/MS). The inhibitory quotient (IQARV) was calculated as the ratio of unbound (bictegravir) or total (emtricitabine and tenofovir) concentration to half (or 90%) maximal inhibitory concentration for bictegravir (or emtricitabine and tenofovir). All numerical variables are expressed as median (range). RESULTS: Twenty-four patients (nine women) were enrolled. The age was 45 (26-68) years. Unbound bictegravir and total emtricitabine and tenofovir CSF concentrations were 4.4 (1.6-9.6), 84.4 (28.6-337.4) and 1.6 (0.7-4.3) ng/mL, respectively. The unbound bictegravir CSF fraction was 34% (15%-82%) versus 0.33% (0.11%-0.92%) in plasma. Three patients had an IQARV above unity for the three antiretrovirals. Factors positively associated with the CSF concentration (unbound for bictegravir) were age and total plasma concentration for the three antiretrovirals. Patients aged over 51 years had higher CSF concentrations (unbound for bictegravir). CONCLUSIONS: We observed low CSF exposure to bictegravir, emtricitabine and tenofovir. These results suggest that BIC/FTC/TAF should be used with caution as first-line treatment for people living with HIV with HCI under 51 years of age.

来源:J Antimicrob Chemother,查看原文。版权归原作者所有。

引用

  1. Gelé T, Chéret A, Castro Gordon A, et al. Cerebrospinal fluid exposure to bictegravir/emtricitabine/tenofovir in HIV-1-infected patients with CNS impairment. J Antimicrob Chemother. 2021. PMID: 34508640. doi:10.1093/jac/dkab334

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。